Acrivon Therapeutics (ACRV) - מזומנים למניה אחת

Acrivon Therapeutics (ACRV) attracts top biologists with R&D freedom and stock options to develop the APCO system. This chart of the liquid position per share on GURU.Markets captures the current trend, where 1.80 indicates the current level. However, risks of secondary offerings and clinical trial uncertainty weigh on the share price, while fierce competition for clinical bases with biotech behemoths intensifies competitive pressure.
פילוחי מדדים מקיפים ואנליטיקה עבור acrivon.com (ACRV)

Cash per share reflects the volume of liquid reserves attributable to a single security. For Acrivon Therapeutics (ACRV), which lacks commercial revenue, the analysis of the issuer's cash per share becomes a key indicator of financial autonomy. This metric demonstrates the biotech's ability to fund costly clinical trials without emergency dilutive secondary offerings. The trend of this indicator determines the business's survival horizon before reaching the monetization stage. This is the primary criterion for assessing the company's stability in the absence of pricing power.